Respondents broadly supported clearer guidance on how evidence on health inequalities should be presented and how impacts are ...

The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

Connecting 80+ EHS experts in pharma and biopharma on the West coast, this year's meeting will address the challenges of ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

For well over a decade, scientists, health leaders, and global organisations have sounded the alarm on antimicrobial ...

The deal for CARGO, which remains relatively well funded despite its troubles, comes with a contingent value right (CVR) that ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

A new player in radioligand therapies (RLTs), Norway and US-based Actithera, has arrived on the scene with $75.5 million in ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

Despite a certain amount of upheaval at the FDA, the agency has continued to keep up with its scheduled approvals and clearances. At BIO 2025, editor-in-chief Jonah Comstock sat down with Mursla Bio ...

Improving efficiencies and uncomplicating processes are critical to the future success of NHS Trusts across the country. The ...

So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...